Pomerantz Law Firm Issues Investor Alert for REGENXBIO Inc. with Class Action Details

Pomerantz Law Firm Issues Investor Alert for REGENXBIO Inc.

On March 5, 2026, Pomerantz LLP announced a significant development for investors in REGENXBIO Inc. (NASDAQ: RGNX), as a class action lawsuit has been launched against the company. This action follows investor concerns regarding potential securities fraud and other illegal business practices associated with REGENXBIO. Investors who believe they have incurred losses on their investment in the company have been advised to reach out to Pomerantz LLP to discuss their situation.

Details of the Class Action Lawsuit

Investors are urged to contact Danielle Peyton via email or phone, providing their personal details and investment history. The strict deadline for individuals wanting to take part in this lawsuit is April 14, 2026, by which time they must seek to be appointed as Lead Plaintiff. The lawsuit's progression will focus on whether REGENXBIO’s directors and officers acted unlawfully, which could significantly impact investor returns.

Background on REGENXBIO

REGENXBIO Inc. specializes in gene therapy and recently faced regulatory scrutiny due to issues revealed during clinical trials. On January 28, 2026, the U.S. Food and Drug Administration (FDA) placed a clinical hold on their investigational gene therapy medicines RGX-111 and RGX-121. This hold was initiated following the analysis of a critical incident involving a participant in a trial, which raised concerns about the safety of these therapies. As a direct consequence of this announcement, the company’s stock plummeted, with a drastic decrease of $2.40 or 17.9%, closing at $11.01 per share on that day.

Legal Understanding and Firm Overview

Pomerantz LLP is well-regarded in the legal space, particularly in corporate and securities class actions. The firm, with its long history dating back over 85 years, prioritizes the protection of individuals who fall victim to securities fraud and corporate misconduct. The firm's impressive track record includes substantial recoveries awarded to class members, underscoring its commitment to achieving justice for investors.

Conclusion

With the class action lawsuit in progress, affected investors should act promptly to evaluate their claims. The stakes are high given the complex nature of the allegations against REGENXBIO. Investors seeking guidance and further information about the lawsuit can visit the Pomerantz website or contact their office directly. Affected parties should not delay as the deadline for participation in this class action is fast approaching. By standing together, investors may protect their interests and seek restitution for their losses due to the alleged fraudulent activities of REGENXBIO.

For legal inquiries or to join the class action, contact Danielle Peyton, Pomerantz LLP at [email protected] or call 646-581-9980.